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Abstract: Several options for the treatment of hepatitis B have been licensed in the last years: 
interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition 
tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The 
antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in 
their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. 
The differing resistance proﬁ  le makes them good combination partners, even in the absence of 
synergy in antiviral potency.
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Introduction
Hepatitis B virus (HBV) infection affects about 2 billion people, of whom about 
350 million display chronic hepatitis B, deﬁ  ned by presence of hepatitis B surface 
antigen (HBsAg) in the serum (Lavanchy 2004). It is estimated that between 235,000 
and 328,000 people die annually due to liver cirrhosis and hepatocellular carcinoma, 
respectively (Perz et al 2006).
Transaminases have for the longest time been the hallmark of liver disease, and 
patients with normal liver transaminases have been considered to have no signiﬁ  cant 
liver disease. Accordingly, guidelines used to state indication for antiviral therapy only 
in the presence of elevated liver enzymes (de Franchis et al 2003; Liaw et al 2005; Lok 
and McMahon 2007). This has, however, been challenged, based on recent ﬁ  ndings 
that high viral load seems more important than elevation of liver transaminases (Chen 
et al 2006; Iloeje et al 2006).
Furthermore, using an antiviral to reduce HBV viral load has been shown to ameliorate 
liver disease (Liaw et al 2004), so that it is now recommended to start antiviral therapy, 
despite normal liver enzymes, when there are other sign of liver disease, such as advanced 
ﬁ  brosis or risk factors to develop hepatocellular carcinoma (Cornberg et al 2007).
There are two different ways to inhibit HBV replication, either by using immune modula-
tors such as interferon, pegylated interferon (Marcellin et al 2004; Lau et al 2005) or thymosin 
alfa (You et al 2006), or with antivirals. Antivirals available at present can then be divided 
into the “lamivudine-like” (L-nucleosides) and the “adefovir-like” drugs. The “lamivudine-
like” and “adefovir-like” drugs differ in their pattern of resistance mutations.
While the “lamivudine-like” antivirals (telbivudine, clevudine, emtricitabin, and 
even entecavir, though additional mutations are required for full resistance in the lat-
ter) share a mutations pattern at position M204 of the YMDD (Tyrosine-Methionine-
Aspartate-Aspartate motif in the catalytic domain of the viral polymerase/reverse 
transcriptase) motif of the HBV-polymerase, the “adefovir-like” antivirals seem to 
remain fully active against those mutants (Yang et al 2005).
The currently licensed and soon to be licensed therapies show differences in 
achieving viral load below a detectability threshold of 300 to 1000 copies per Therapeutics and Clinical Risk Management 2008:4(4) 798
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ml, as indicated in Figure 1. Additionally, they differ 
in their selection for viral resistance, which has not yet 
been reported for interferon, but for all antivirals to 
different degree.
Nonresponse to interferon might be more based on the 
cellular than on the viral level, as has been demonstrated 
in case of HCV infection (Aus dem Siepen et al 2007). In 
contrast to interferon, resistance to antivirals can occur 
frequently, especially in case of insufﬁ  cient response (Han 
et al 2007). Resistance after one year ranges from below 1% 
in adefovir (Hadziyannis et al 2003; Marcellin et al 2003) 
and entecavir (Chang et al 2006; Lai et al 2006a) to about 
32% in lamivudine-treated patients (Dienstag et al 1999). 
Long term data on resistance are scarce. There are no real 
controlled data for lamivudine, but it is generally presumed 
to rise to about 70% over 5 years. Likewise, it has been 
shown that resistance to adefovir emerges with a constant 
increase from 0%, 3%, 9%, and 18% to 29% within 1, 2, 
3, 4, and 5 years, respectively, in HBeAg-negative patients 
years (Hadziyannis et al 2006). In addition, one must be 
aware that the chance of developing resistance is higher 
in HBeAg-positive vs. HBeAg-negative patients (Table 1) 
(Han et al 2007). For telbivudine reliable 1 and 2 year 
data are available, while data for entecavir only included 
subgroups of their patients (Colonno et al 2006), thus 
making ﬁ  nal conclusions difﬁ  cult. The risk for entecavir 
resistance is significantly increased with underlying 
lamivudine resistance (Colonno et al 2006).
Adefovir
When adefovir was initially developed for HIV therapy, its 
development was halted due to nephrotoxicity at the doses 
of 60 and 120 mg, which would have been required for HIV 
therapy (Kahn et al 1999). Because of its anti-HBV-activity, 
adefovir was still further evaluated for treatment of HBV, 
where a 10 mg dose was shown to be sufﬁ  cient to suppress 
HBV to similar levels as lamivudine, while in that dose there 
was no signiﬁ  cant nephrotoxicity or other toxicity (Izzedine 
et al 2004).
A clear strength of the adefovir-like nucleosides is 
their higher genetic barrier to resistance. Though there are 
no “head to head” studies, adefovir in the licensed 10 mg 
dose is at least not more efﬁ  cient than lamivudine, given in 
100 mg. Still the resistance rate is much lower for adefovir, 
with “zero” after one year (Hadziyannis et al 2003; Marcellin 
et al 2003). However, it has been noted that resistance to 
adefovir develops more frequently in the presence of under-
lying lamivudine resistance, if lamivudine is not continued 
(van der Poorten et al 2007).
Furthermore, it has been demonstrated that the 30 mg 
dose of adefovir would be superior than the 10 mg con-
cerning antiviral efﬁ  cacy (Marcellin et al 2003), which 
was recently reinforced by a study using 20 mg daily in 
5 lamivudine-resistant patients with insufﬁ  cient response 
to the 10 mg adefovir dose (Hezode et al 2007). Thus, a 
higher dose of adefovir would be desired, but the 30 mg 
dose was shown to lead to a signiﬁ  cantly more frequent 
Figure 1 Efﬁ  cacy of HBV drugs (48–52 week data). Lai CL, et al. Hepatology 2005; 42:748A (AASLD abstract LB01); Lau G, et al. NEJM 2005; 352:2882–2695; Chang T-T, et al. 
NEJM 2006; 354:1000–1010; Marcellin P, et al. NEJM 2003;348:808–816. #Heathcote J et al. AASLD 2007, Marcellin P, et al.   AASLD 2007.
Notes: *Undetectable 300 copies/mL, #Undetectable 400 copies/mL, §Undetectable 1000 copies/mL.
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Table 1 Resistance deﬁ  ned by 1 log viral load increase over nadir after one and two years within the GLOBE trial
Rate of resistance  Lamivudine    Telbivudine 
  HBeAg-positive HBeAg-negative HBeAg-positive HBeAg-negative
Year  1  8.2 3.0  8.5 2.1
Year  2 35.0 21,6  21.6 8.6
Adapted from Han et al (2007).
increase in creatinine levels than the 10 mg dose (Marcellin 
et al 2003).
The viral load reduction achieved by lamivudine is no lon-
ger the standard, but instead the viral load reduction achieved 
by entecevair and telbivudine is preferred, both leading to 
more than 6 log viral load reduction (Chang et al 2006; Han 
et al 2007). As a result, it would be more beneﬁ  cial to utilise 
adefovir-like drugs, with both higher antiviral activity and 
lower toxicities. Adefovir-like drugs are currently prade-
fovir (also known as remofovir; almefovir; Hepavir B™) 
(Tillmann 2007), which is a prodrug of adefovir, tenofovir, 
LB-80380 (also known as ANA 380) and alamifovir (also 
known as MCC-478) (Chan et al 2005).
Pradefovir, a liver-targeted adefovir
Based on the concept of increased levels of adefovir at 
the main target organ, the liver, with low systemic expo-
sure, pradefovir was developed. Pradefovir (also known 
as remofovir; almefovir; Hepavir B) is based on adefovir 
and a speciﬁ  c side chain making it into an inert drug, until 
activation through cytochrome p450 (CYP3A4). As this 
compound is abundant in the liver but scarce elsewhere 
in the body (Berggren et al 2007), it is almost exclusively 
activated in the liver, thereby high drug levels are achieved 
in the liver, while the systemic exposure has been shown to 
be low (Lin et al 2004).
Dependence on CYP3A4, however, makes pradefovir 
prone to interaction with other drugs that also require, 
induce or inhibit CYP3A4. In line with the need for further 
metabolization, the AUC variation was higher on prade-
fovir compared to adefovir (Lee et al 2006). The antiviral 
activity in that phase II study was more pronounced on 
pradefovir doses of 10 mg and higher. The open-label 
phase II trials compared pradefovir (5, 10, 20, or 30 
mg) with 10 mg adefovir in chronically HBV-infected 
patients, who were treated for 24 to 48 weeks (Lee et al 
2006, Lin et al 2006) This study included 47, 49, 48, 48, 
and 50 patients into the pradefovir 5, 10, 20 and 30 mg 
arm and the 10 mg adefovir arm respectively. After 24 
and 48 weeks, a viral reduction was described to be 3.39, 
4.22, 4.33, and 5.02 log copies per ml for the pradefovir 
mesylate dose of 5, 10, 20, and 30 mg, respectively, 
compared with 3.66 with 10 mg adefovir dipivoxil after 
24 weeks (Lee et al 2006) and 4.09, 4.84, 4.89, 5.54 log 
copies per ml for the pradefovir mesylate dose of 5, 10, 
20, and 30 mg, respectively, compared to 4.19 on 10 mg 
adefovir dipivoxil after 48 weeks (Lin et al 2006). How-
ever, pradefovir was recently put on hold concerning its 
further development based on increased tumor incidence 
in animal studies (Tillmann 2007). At present, it is unclear 
whether this is a class effect of “adefovir-like” substances, 
the high doses of adefovir in the liver, or related to the 
prodrug delivery used here.
Tenofovir
Tenofovir as adefovir was developed for HIV therapy and 
has proven to have lower renal toxicity and good activity, 
actually making it currently one of the top nucleoside reverse 
transcriptase inhibitor backbones in therapies for HIV (De 
Clercq 2007). Nonetheless, renal toxicity is still a concern in 
relation to tenofovir, though not quite proven to be causally 
associated (Röling et al 2006). It has been demonstrated 
in some case series that tenofovir, at least in the dose of 
245 mg tenofovir dipivoxil equivalent to 300 mg tenofovir 
dipivoxil fumarate equivalent to 136 mg tenofovir as given for 
HIV, is superior to the 10 mg dose of adefovir (van Bömmel 
et al 2004), which has been reinforced by reactivation after 
switching from tenofovir to adefovir (van Bömmel and Berg 
2005; Del Poggio et al 2007) and improved suppression 
after switching from adefovir to tenofovir (van Bömmel et al 
2006). A trend towards better response has also been seen 
in a placebo controlled trial of HIV infected patients (Peters 
et al 2006).
There are two controlled trials currently underway 
comparing tenofovir to adefovir, which have only been 
presented as press releases (Gilead 2007a, 2007b) and 
abstract form. The one year data have been presented at 
the 2007 AASLD (American Association for the Study 
of the Liver) annual meeting. According to these press 
releases and the presentations (Heathcote et al 2007; 
Marcellin et al 2007), Tenofovir is signiﬁ  cantly more 
potent than adefovir. Tenofovir achieved the highest rates Therapeutics and Clinical Risk Management 2008:4(4) 800
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in undetectability of HBV-DNA observed in any drug trial 
related to hepatitis B. However, the comparison to the 
other currently marketed drug is difﬁ  cult given that the 
viral load of the enrolled patients was in average about 1 
log lower than in the other trials. It might well be that the 
antiviral efﬁ  cacy is superior to that of the other currently 
marketed drugs. However, to ﬁ  nally asses this, a head to 
head study would be required, but unlikely to take place. 
However, in addition to its efﬁ  cacy, no emergence of viral 
breakthrough has been observed on tenofovir. In addition, 
HBsAg loss, otherwise mostly only seen in relation to 
interferon-based therapies has been observed in about 3% 
after 48 weeks and 4% of tenofovir-treated patients after 
69 weeks of therapy (Heathcote et al 2008). However, 
no loss of HBsAg has been observed in HBeAg-negative 
patients on tenofovir.
After tenofovir’s licensure for HBV therapy, it is prob-
able that adefovir’s only indication will be the HIV-positive 
patient needing HBV-treatment, but not yet requiring anti-
HIV therapy (Thio and Locarnini 2007).
A mutation, rtA194T, has been reported to emerge on 
tenofovir (Sheldon et al 2005), but it did not lead to a real 
viral load increase, thus awaiting further conﬁ  rmation.
Alamifovir
Alamifovir, also known as MCC-478 or LY582563, is a 
adenosine nucleotide analogue, which has activity against 
both HIV and HBV. In a phase I study 66 HBV-DNA posi-
tive patients were randomized to alamifovir or placebo in a 
3:1 ratio within each of 7 dosing groups: 2.5 mg BID, 5 mg 
BID, 10 mg BID, 2.5 mg QD, 5 mg QD, 10 mg QD, and 
20 mg QD. That study showed no difference between once 
daily and twice daily dosing (Table 2). In this small study, 
there were also no signiﬁ  cant differences between the groups 
except towards placebo. At present, no new data have been 
presented within the last two years.
LB-80380
LB-80380 is also known as ANA 380, and is a 9-[1-(Ph
osphonomethoxycyclopropyl) methyl] guanine (PMCG). 
Even though it is frequently regarded as a “adefovir-like” 
nucleotide, it is considered, at least by some, as a 
representative of a novel class of phosphonate nucleosides 
that blocks HBV replication with an excellent potency 
(EC50 of 0.5 μM) in HepG2 2.2.15 cells (Choi et al 2004). 
LB-80380 did not show any cytotoxicity in several human 
cell lines in concentrations up to 2000 times of that required 
for an EC50 for HBV inhibition. It seems not to inhibit 
HIV replication, at least at 30 μM, which is 60 times the 
dose required for HBV. This, however, requires further 
evaluation in light of the unexpected activity of entecavir 
against HIV (McMahon et al 2007). Furthermore, in 
its oral form, PMCDG dipivoxil, excellent efficacy was 
achieved in HBV infected woodchucks at 5 mg/kg/d (Choi 
et al 2004).
In vivo LB-80380 has been also tested in naïve and lami-
vudine refractory patients (Yuen et al 2006). When doses of 
30, 60, 120, and 240 mg were given once daily for 4 weeks, 
a mean maximum viral load reduction of 3.05, 4.20, 3.67, 
and 3.68 log10 copies/ml was achieved for the 30, 60, 120, 
and 240 mg doses, respectively, in naïve patients (Yuen et al 
2006). Slightly lower reduction was achieved in lamivudine 
refractory patients with 2.1, 2.5, 2.6, 3.0, and 3.0 log10 as 
well as 2.8, 3.2, 3.9, and 3.7 log10 after 4 and 12 weeks, 
respectively in the 30, 60, 90, 150, and 240 mg dose groups 
(Lai et al 2006b).
Conclusions
In summary, the “adefovir-like” drugs best used in practice 
are adefovir in the HIV-infected patient in need of anti-HBV 
therapy, while not yet needing anti-HIV therapy (Thio and 
Locarnini 2007). In all other patients, I would presume teno-
fovir to take over, where adefovir is currently used given its 
lower toxicity and higher activity. Whether any of the other 
“adefovir-like” drugs will make it to the market remains 
to be seen. It is probable that all could be well combined 
with lamivudine, which will soon be off-patent. Thus, it 
might be a cheap but potentially very active addition to any 
“adefovir-like” drug, given their different resistance proﬁ  le. 
However, in the case of tenofovir, this is not required, given 
its existence in combination with the lamivudine-like drug 
emtricitabine.
Table 2 Viral load reduction on alamifovir
      2.5 mg/d  5 mg/d    10 mg/d    20 mg/d 
Parameter  N  Placebo  2.5 mg   2.5 mg   5 mg   5 mg   10 mg   10 mg   20 mg 
     QD  BID  QD  BID  QD  BID  QD
Log-change on day 29  Mean drop  0,064  1,52  2,02  1,96  1,98  2,49  2,53  2,50Therapeutics and Clinical Risk Management 2008:4(4) 801
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